BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD

Core Viewpoint - Ocular Therapeutix Inc. (NASDAQ:OCUL) is identified as a low-priced stock with significant upside potential, particularly due to its drug AXPAXLI, which targets wet AMD and diabetic retinopathy [1][3]. Group 1: Regulatory Strategy and Drug Development - On December 8, Ocular Therapeutix announced an acceleration of its regulatory strategy for AXPAXLI, planning to submit a New Drug Application (NDA) shortly after receiving one-year data from its SOL-1 Phase 3 trial, contingent on positive results [2]. - The topline results from the SOL-1 trial are expected to be released in Q1 2026 [2]. - The FDA has provided guidance indicating that a single, well-powered registrational trial may be sufficient for approval, which could expedite the regulatory process for AXPAXLI [3]. Group 2: Clinical Trial Details - The SOL-1 study, which completed randomization in December 2024, involves 344 treatment-naïve subjects and compares AXPAXLI against a 2 mg dose of aflibercept [3]. - The primary endpoint of the SOL-1 trial measures the proportion of patients maintaining visual acuity at week 36, supporting the drug's potential for a superiority label [3]. Group 3: Market Position and Analyst Sentiment - Bank of America has raised the price target for Ocular Therapeutix from $18 to $21 while maintaining a Buy rating, reflecting optimism about the company's development strategy and competitive advantages [1]. - The firm hosted CEO Pravin Dugel to discuss upcoming corporate milestones, reinforcing confidence in the company's direction [1]. Group 4: Company Overview - Ocular Therapeutix is a biopharmaceutical company focused on developing and commercializing therapies for retinal diseases and other eye conditions using bioresorbable hydrogel-based formulation technology in the US [4].